Prospective,Double-blind,Randomized,Placebo-controlled Study of Safety,Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers
Latest Information Update: 17 Nov 2021
Price :
$35 *
At a glance
- Drugs ACD 440 (Primary)
- Indications Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors AlzeCure
- 08 Nov 2021 Status changed from recruiting to completed.
- 20 Jan 2021 Status changed from not yet recruiting to recruiting.
- 08 Jan 2021 Status changed from planning to not yet recruiting.